Flavio Caprioli
University of Milan
Internal medicineTumor necrosis factor alphaImmunologyColitisVedolizumabInflammationInfliximabLamina propriaInflammatory Bowel DiseasesInflammatory bowel diseaseCytokineDiseaseCrohn's diseaseUlcerative colitisIn patientCancer researchMedicineBiologyImmune systemGastroenterology
220Publications
36H-index
4,425Citations
Publications 222
Newest
#1Flavio Caprioli (University of Milan)H-Index: 36
#2Marco DapernoH-Index: 29
Last. Antonio Rispo (University of Naples Federico II)H-Index: 27
view all 7 authors...
OBJECTIVES Anti-TNFα agents have been a staple of Crohn's disease treatment for 20 years, but they have weaknesses. New treatments have more recently become available. The aim of this paper is to examine the Crohn's disease patient population for whom anti-TNF treatments are not preferred and where new mechanisms of action should be considered. METHODS A representative sample of 100 Italian physicians with documented expertise with biological treatment of moderate-to-severe Crohn's disease were ...
Source
#2Roberto Penagini (University of Milan)H-Index: 30
view all 33 authors...
Objective We aimed to investigate the relation of blood bacterial DNA load and profiling with intestinal adenoma (IA) and colorectal cancer (CRC) patients. Design We performed 16S rRNA gene analysis of blood from 100 incident histologically confirmed CRC cases, 100 IA and 100 healthy subjects, matched to cases by centre, sex and age. Bacterial load was analysed using multiple conditional logistic regression. Differences in terms of abundance of bacteria between groups were estimated through anal...
Source
#1Marten Beeg (Mario Negri Institute for Pharmacological Research)H-Index: 18
Last. Marco Gobbi (Mario Negri Institute for Pharmacological Research)H-Index: 58
view all 9 authors...
Measurements of serum concentrations of therapeutic antibodies and anti-drug antibodies (ADA) can support clinical decisions for the management of non-responders, optimizing the therapy. In the present study we compared the results obtained by classical ELISA and a recently proposed surface plasmon resonance (SPR)-based immunoassay, in 76 patients receiving infliximab for inflammatory bowel diseases. The two methods indicated very similar serum concentrations of the drug, but there were striking...
Source
#1Andrea CostantinoH-Index: 4
#2Daniele Noviello (University of Milan)H-Index: 2
Last. Giammarco MocciH-Index: 13
view all 18 authors...
Source
#1Sandro Ardizzone (University of Milan)H-Index: 66
#2Francesca Ferretti (University of Milan)H-Index: 11
Last. Stefano MazzaH-Index: 7
view all 24 authors...
BACKGROUND AND AIM: Since the outbreak of COVID-19, concerns have been raised as to whether inflammatory bowel disease (IBD) patients under biologic therapy may be more susceptible to the disease. This study aimed to determine the incidence and outcomes of COVID-19 in a large cohort of IBD patients on biologic therapy. METHODS: This observational retrospective multicenter study collected data about COVID-19 in IBD patients on biologic therapy in Italy, between February and May 2020. The main end...
Source
#1Cristina BezzioH-Index: 11
#2Alessandro ArmuzziH-Index: 58
Last. Chiara Viganò (University of Milano-Bicocca)H-Index: 6
view all 39 authors...
Background: Patients with Inflammatory bowel disease (IBD) are not at high risk of contracting SARS-CoV-2 infection or developing COVID-19 compared to the general population, nor are they at greater risk of negative outcomes. The main risk factors for negative COVID-19 outcomes in IBD patients are older age and comorbidities. The impact of IBD medications on both infection rates and disease severity is unclear. We assessed risk factors for negative outcomes of COVID-19 in IBD patients and used t...
#1Stefano Mazza (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 7
#2Francesco Simone Conforti (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Last. Maurizio Vecchi (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 54
view all 11 authors...
BACKGROUND the assessment of fibrosis in Crohn's disease (CD) bowel lesions helps to guide therapeutic decisions. Real-time elastography (RTE) and delayed-enhancement magnetic resonance enterography (DE-MRE) have demonstrated good accuracy in quantifying CD-related ileal fibrosis as compared with histological examination. To date no study has compared DE-MRE and RTE. AIMS we aimed to evaluate the agreement between RTE and DE-MRE on quantifying CD-related ileal fibrosis. METHODS consecutive patie...
Source
Source
Source
#1Bruno RosaH-Index: 18
#2Reuma Margalit-Yehuda (Sheba Medical Center)H-Index: 2
Last. Anastasios KoulaouzidisH-Index: 32
view all 15 authors...
Source